skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

The use of anti-TNFα medications for rheumatologic disease in pregnancy

Review

(2085) Views  (600) Full article downloads

Authors: Megan EB Clowse

Published Date June 2010 Volume 2010:2 Pages 199 - 209
DOI: http://dx.doi.org/10.2147/IJWH.S6029

Megan EB Clowse

Division of Rheumatology and Immunology, Department of Medicine, Duke University Medical Center, Durham, NC, USA

Abstract: Anti-TNFα medications have led to vast improvements in the treatment of inflammatory conditions, including rheumatoid arthritis and Crohn’s disease. As these diseases often afflict women in their reproductive years, the safety of these drugs during pregnancy is an important issue. Prospectively collected data thus far appear to be reassuring; however an analysis of the FDA-reported anomalies has raised some questions. It appears that significant levels of these drugs cross the placenta as the pregnancy nears term, but little is passed through breast milk. Prior to using these medications during pregnancy, the risks and benefits of these drugs, other treatment options, and the ongoing inflammatory condition all must be carefully weighed by both doctor and patient.

Keywords: pregnancy, anti-TNFα medications, rheumatoid arthritis, Crohn’s disease, teratogenesis








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
The triple test as a screening technique for Down syndrome: reliability and relevance
Management of preterm labor: atosiban or nifedipine?
Optimal management of perimenopausal depression
Partner violence during pregnancy: prevalence, effects, screening, and management
Long-term safety, efficacy, and patient acceptability of the intrauterine Copper T-380A contraceptive device
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy